Phase II AVANOVA2: Niraparib + Bevacizumab vs Niraparib Alone in Platinum-Sensitive Recurrent Ovarian Cancer

May 31 - June 4, 2019; Chicago, Illinois
In patients with recurrent ovarian cancer, the chemotherapy-free combination of niraparib plus bevacizumab significantly improved PFS vs niraparib alone, regardless of HRD status or chemotherapy-free interval.
Format: Microsoft PowerPoint (.ppt)
File Size: 197 KB
Released: June 7, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an educational grant from
Tesaro

Related Content

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

On-demand webcast from a live Clinical Care Options (CCO) webinar on global perspectives on the use of PARP inhibitors for ovarian cancer, facilitated by Jonathan A. Ledermann, MD

Prof Jonathan A. Ledermann, MD, FRCP, FMed Sci person default Frederik Marmé, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 20, 2021 Expired: July 19, 2022

Downloadable PDF with highlights from a CCO podcast on managing endometrial and ovarian cancer with targeted therapies.

Robert L. Coleman, MD, FACOG, FACS Linda R. Duska, MD, MPH Leslie M. Randall, MD, MAS, FACS Released: July 16, 2021

On-demand webcast on recent advances in endometrial, ovarian, cervical cancers, including updates from the 2021 ASCO annual meeting, from Clinical Care Options (CCO)

Robert L. Coleman, MD, FACOG, FACS Linda R. Duska, MD, MPH Leslie M. Randall, MD, MAS, FACS Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 15, 2021 Expired: July 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue